Recently Featured

CAR-T Therapy Shows Promise in Smoldering Myeloma at AACR

April 29, 2026
At the AACR annual meeting, Dana-Farber Cancer Institute presented compelling data from an early phase trial involving Carvykti, a BCMA-directed CAR-T therapy, administered to 20 patients with high-risk smoldering multiple myeloma. This innovative approach aims to intervene in the precursor stage of the disease, potentially staving off the progression to active multiple myeloma in those…

CAR-T Therapy Shows Promising Results in Preventing Multiple Myeloma in High-Risk Patients

April 29, 2026
SAN DIEGO — A recent clinical trial presented at the American Association for Cancer Research meeting has revealed that all 20 patients treated with CAR-T therapy for smoldering multiple myeloma exhibited no detectable myeloma cells post-treatment. This outcome is particularly significant as it surpasses the typical responses observed in multiple myeloma cases, raising hopes that…

RFK Jr. defends HHS tenure amid proposed 12% budget cut

April 28, 2026
During a series of House hearings last week, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. received commendations from Republican lawmakers for his tenure, yet he faced scrutiny regarding proposed budget cuts to the National Institutes of Health (NIH). The proposed 12% reduction raises significant concerns among stakeholders in the pharmaceutical and biotech…

Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline

April 28, 2026
Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, a strategic move aimed at enhancing its oncology pipeline with an innovative lentiviral in vivo chimeric antigen receptor T-cell (CAR T) therapy currently in clinical trials for relapsed/refractory multiple myeloma. This acquisition underscores Lilly’s commitment to advancing cancer therapies, particularly as the…

Ongoing Cases